Announced
Completed
Synopsis
venBio, a life sciences investment firm, Foresite Capital, an American venture capital and growth equity firm, and Decheng Capital, an investment company, led a $111m Series B round in ImmPact Bio, a biotechnology company, with participation from OrbiMed, Surveyor Capital and Novartis Venture Fund. "We believe ImmPACT Bio's technology platforms will help to expand the curative potential of cell therapies in certain cancers and to address challenges that have limited the efficacy of cell therapies in hard-to-treat tumor types. We are excited to work with the scientists and clinicians at ImmPACT Bio to translate their engineering innovations into novel cell therapy products for multiple malignancies," Richard Gaste, venBio Partners Managing Partner.
Show Details & Financials
Sort
Search a database of more than 250,000 verified dealmakers
Receive automated updates on global transactions
Follow the activity, relationships and transactions of top dealmakers
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.